Bioavailability & Bioequivalence Studies MCQs With Answer

Bioavailability & Bioequivalence Studies MCQs With Answer

by

Bioavailability & Bioequivalence Studies MCQs With Answer

Introduction: This quiz collection is designed for M.Pharm students taking MIP 201T – Advanced Biopharmaceutics & Pharmacokinetics. It covers core concepts and practical considerations in bioavailability (BA) and bioequivalence (BE) studies, including PK parameters, study designs, statistical approaches, regulatory criteria, BCS-based biowaivers, in vitro–in vivo correlations, and special cases like highly variable and narrow therapeutic index drugs. Each question emphasizes applied understanding needed for designing, analyzing, and interpreting BA/BE experiments. Use these MCQs to strengthen conceptual clarity, prepare for examinations, and review real-world regulatory expectations and methodological strategies essential for pharmaceutical development and quality assessment.

Q1. Which pharmacokinetic parameter is most commonly used to quantify the overall extent of systemic exposure after extravascular administration compared to an intravenous dose?

  • Maximum plasma concentration (Cmax)
  • Area under the plasma concentration–time curve (AUC)
  • Time to reach maximum concentration (Tmax)
  • Elimination half‑life (t1/2)

Correct Answer: Area under the plasma concentration–time curve (AUC)

Q2. Absolute bioavailability (F) is calculated by which expression?

  • (AUCpo / AUCiv) × (Dose PO / Dose IV)
  • (AUCiv / AUCpo) × (Dose PO / Dose IV)
  • (AUCpo / AUCiv) × (Dose IV / Dose PO)
  • (Cmax,po / Cmax,iv) × (Dose IV / Dose PO)

Correct Answer: (AUCpo / AUCiv) × (Dose IV / Dose PO)

Q3. Which statement best describes the interpretation of Cmax in bioavailability studies?

  • Cmax exclusively measures the extent of absorption.
  • Cmax exclusively measures the rate of elimination.
  • Cmax is primarily an indicator influenced by both rate and extent of absorption.
  • Cmax is unrelated to absorption and reflects distribution only.

Correct Answer: Cmax is primarily an indicator influenced by both rate and extent of absorption.

Q4. Which study design is the default most appropriate for single‑dose bioequivalence studies in healthy volunteers?

  • Randomized two‑period two‑sequence crossover design
  • Parallel group design without crossover
  • Factorial design with dose escalation
  • Open‑label uncontrolled study

Correct Answer: Randomized two‑period two‑sequence crossover design

Q5. What is the standard recommendation for the washout period between periods in a crossover BE study?

  • At least one half‑life of the drug
  • At least three half‑lives of the drug
  • At least five half‑lives of the drug
  • No washout period is necessary

Correct Answer: At least five half‑lives of the drug

Q6. Which statistical approach is most commonly used to assess average bioequivalence?

  • Two one‑sided t‑tests (TOST) on log‑transformed data
  • One‑sided Wilcoxon signed‑rank test
  • Chi‑square test for proportions
  • Untransformed paired t‑test

Correct Answer: Two one‑sided t‑tests (TOST) on log‑transformed data

Q7. What are the conventional regulatory acceptance limits for the geometric mean ratio of AUC and Cmax in most BE studies?

  • 70–143%
  • 75–125%
  • 80–125%
  • 90–111%

Correct Answer: 80–125%

Q8. Why are AUC and Cmax usually log‑transformed before statistical analysis in BE studies?

  • To convert all measures into percentages
  • Because PK parameters are normally distributed in raw scale
  • To stabilize variance and permit ratio (geometric mean) interpretation
  • To avoid calculating confidence intervals

Correct Answer: To stabilize variance and permit ratio (geometric mean) interpretation

Q9. What confidence interval level is typically reported for bioequivalence acceptance?

  • 95% two‑sided CI
  • 90% two‑sided CI
  • 99% two‑sided CI
  • 80% two‑sided CI

Correct Answer: 90% two‑sided CI

Q10. According to the Biopharmaceutics Classification System (BCS), which class is the primary candidate for a biowaiver for immediate‑release solid oral dosage forms?

  • BCS Class II (low solubility, high permeability)
  • BCS Class I (high solubility, high permeability)
  • BCS Class IV (low solubility, low permeability)
  • BCS Class III (high solubility, low permeability)

Correct Answer: BCS Class I (high solubility, high permeability)

Q11. Which pair of pharmacokinetic endpoints is universally regarded as the primary measures in most BE assessments?

  • Tmax and elimination half‑life
  • AUC and Cmax
  • Volume of distribution and clearance
  • Apparent absorption rate constant and bioavailability fraction

Correct Answer: AUC and Cmax

Q12. Which statistical method is generally recommended for comparing Tmax between two formulations?

  • Parametric t‑test on log‑transformed Tmax
  • Nonparametric tests (e.g., Wilcoxon signed‑rank test)
  • ANOVA on untransformed Tmax
  • Chi‑square test

Correct Answer: Nonparametric tests (e.g., Wilcoxon signed‑rank test)

Q13. When is reference‑scaled average bioequivalence (RSABE) typically applied?

  • For drugs with low within‑subject variability (<10% CV)
  • For highly variable drugs with within‑subject CV usually >30%
  • Only for topical products
  • For parenteral solutions with immediate distribution

Correct Answer: For highly variable drugs with within‑subject CV usually >30%

Q14. Which in vitro metric is commonly used to compare dissolution profiles between two immediate‑release products?

  • f1 difference factor with acceptable range 50–100
  • f2 similarity factor with acceptable range 50–100
  • Correlation coefficient r with acceptable range 0.1–0.3
  • Mean dissolution time (MDT) only

Correct Answer: f2 similarity factor with acceptable range 50–100

Q15. Which strategy is most effective in minimizing carryover effects in a crossover BE study?

  • Shorten the sampling period
  • Increase the washout period sufficiently
  • Reduce the number of subjects
  • Use a higher test dose

Correct Answer: Increase the washout period sufficiently

Q16. Which numerical method is most commonly used to calculate AUC from observed concentration–time data in noncompartmental analysis?

  • Simpson’s rule
  • Trapezoidal rule
  • Fourier transform
  • Maximum likelihood estimation

Correct Answer: Trapezoidal rule

Q17. Which study design allows direct estimation of within‑subject variability for both test and reference formulations?

  • Simple 2×2 crossover design
  • Parallel group design
  • Replicate crossover design (e.g., 2×2×4)
  • Single arm open‑label study

Correct Answer: Replicate crossover design (e.g., 2×2×4)

Q18. If the geometric mean ratio (GMR) for AUC of test/reference is 0.95, how should this be interpreted?

  • The test product produces 95% of the exposure of reference on average
  • The test product is 5% more bioavailable than the reference
  • The test product is not bioequivalent because GMR must equal 1.00
  • The test product has a 95% probability of being safe

Correct Answer: The test product produces 95% of the exposure of reference on average

Q19. How are bioequivalence requirements typically adjusted for narrow therapeutic index (NTI) drugs compared with standard drugs?

  • NTI drugs are exempt from bioequivalence testing
  • NTI drugs generally require wider BE limits than 80–125%
  • NTI drugs may require tighter BE limits than 80–125% or case‑by‑case stricter criteria
  • NTI drugs use only Tmax as the BE endpoint

Correct Answer: NTI drugs may require tighter BE limits than 80–125% or case‑by‑case stricter criteria

Q20. Which factor has the largest influence on the sample size required to achieve adequate power in a crossover BE study?

  • The expected geometric mean ratio (difference between formulations)
  • The within‑subject variability of the pharmacokinetic metrics
  • The number of sampling points after dosing
  • The analytical lower limit of quantification only

Correct Answer: The within‑subject variability of the pharmacokinetic metrics

Leave a Comment